SYDNEY, April 15 (Reuters) - Shares of China's Duality Biotherapeutics 9606.HK were set to rise 91.3% in their Hong Kong debut on Tuesday after the company raised $213 million in an initial public offering launched as financial markets reacted savagely to the U.S tariffs package.
(Reporting by Scott Murdoch in Sydney and Donny Kwok in Hong Kong; Editing by Tom Hogue)
((Scott.Murdoch@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.